9 results

  • actimmune

    (Interferon gamma-1b)
    Horizon Therapeutics USA, Inc.
    ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).

  • duexis

    (Ibuprofen and Famotidine)
    Horizon Therapeutics USA, Inc.
    DUEXIS is indicated for relieving symptoms of rheumatoid arthritis and osteoarthritis, and for reducing the risk of upper gastrointestinal ulcers in patients taking ibuprofen for these conditions. It is primarily studied in patients under 65 without a history of gastrointestinal ulcers. Controlled trials lasted up to 6 months.

  • krystexxa

    (pegloticase)
    Horizon Therapeutics USA, Inc.
    KRYSTEXXA (pegloticase) is indicated for treating chronic gout in adult patients who are refractory to conventional therapy, meaning they have not achieved normalized serum uric acid levels or adequately controlled symptoms with maximum doses of xanthine oxidase inhibitors. It is not recommended for asymptomatic hyperuricemia.

  • pennsaid

    (diclofenac sodium)
    Horizon Therapeutics USA, Inc.
    PENNSAID is indicated for the treatment of pain associated with osteoarthritis of the knee(s).

  • procysbi

    (Cysteamine bitartrate)
    Horizon Therapeutics USA, Inc.
    PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients aged 1 year and older.

  • rayos

    (prednisone)
    Horizon Therapeutics USA, Inc.
    RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

  • tepezza

    (teprotumumab)
    Horizon Therapeutics USA, Inc.
    TEPEZZA is indicated for the treatment of Thyroid Eye Disease, applicable to patients regardless of the disease's activity level or duration.

  • uplizna

    (Inebilizumab)
    Horizon Therapeutics USA, Inc.
    UPLIZNA is indicated for treating neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive and for treating Immunoglobulin G4-related disease (IgG4-RD) in adult patients.

  • vimovo

    (Naproxen and Esomeprazole Magnesium)
    Horizon Therapeutics USA, Inc.
    VIMOVO, a combination of naproxen and esomeprazole magnesium, is indicated for symptomatic relief of arthritis in adults and adolescents (ages 12+), while helping to reduce the risk of naproxen-associated gastric ulcers. It's not recommended for initial acute pain treatment and is not a substitute for single-ingredient products.